Cytomegalovirus Infection Clinical Trial
Official title:
A Multi-Site, Randomized Trial of Subject-Collected Dried Blood Spot CMV Testing With Mobile Technology Support to Optimize Preemptive Therapy Late After Allogeneic HCT
Verified date | May 2024 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized clinical trial to assess whether a subject centered, self-collection of Dried blood spots (DBS) samples will improve compliance with the clinical recommendation of weekly Cytomegalovirus (CMV) testing of Hematopoietic cell transplantation (HCT) recipients who are at high risk for late CMV disease. In this study, mobile devices will be used to remind HCT survivors to perform CMV monitoring using finger-stick collected DBS testing in their home setting or to visit their doctor's office to perform the test. 150 allogeneic HCT recipients > /= 15 years of age will be randomized (2:1) to DBS monitoring or standard of care (per local institution) monitoring. Duration of study participation is anticipated to be within a range of 26 weeks to 43 weeks. The primary objective is to evaluate adherence to recommended CMV monitoring duration and interval during the first year after HCT upon enrollment using subject collected dried blood spot testing.
Status | Active, not recruiting |
Enrollment | 622 |
Est. completion date | August 25, 2024 |
Est. primary completion date | January 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 99 Years |
Eligibility | Inclusion Criteria: Randomized Cohort: 1. Must be >/= 15 years of age at the time of enrollment 2. Must be able to provide written consent and complete the informed consent 3. Must have received allogeneic hematopoietic cell transplantation within 60-180 days prior to randomization 4. Cytomegalovirus (CMV) seropositive or had a donor who was CMV positive 5. One or both of the following: - CMV event* within the first 100 days post-transplant requiring anti-viral treatment - Receipt of CMV prophylaxis**(for at least 30 days) prior to randomization. Continuation of letermovir prophylaxis after day 100 per institutional standard of care is permitted * CMV event defined as deoxyribonucleic acid (DNA) detection or disease ** Anti-viral treatment or prophylaxis includes ganciclovir, valganciclovir, foscarnet, or letermovir 6. Direct availability to the internet either by a computer in the residence or a smart phone 7. Had at least one or more of these conditions: - HLA mismatch* - umbilical cord blood source** - Graft versus host disease (GVHD)*** - T-cell depletion**** * Human leukocyte antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B, or -DR, Haploidentical donor, Unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1 - Use of umbilical cord blood as stem cell source ***Acute or chronic GVHD requiring topical steroid for gastrointestinal (GI) GVHD and/or systemic steroid treatment (>/= 1 mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 6 weeks prior to enrollment - Subjects who have received partial or full T-cell depletion (with or without GVHD). T-cell depletion can be given as either ex-vivo or in-vivo for GVHD prophylaxis. T-cell depleting agents include, but are not limited to, anti-thymocyte globulin (ATG) and alemtuzumab Observation Cohort: 1. Must be >/= 15 years of age at the time of enrollment 2. Must have one of the following: - Consented for retrospective studies at their transplant center, or - Be included under the auspices of the site's IRB approved waiver of additional consent for retrospective studies 3. Must have received allogeneic hematopoietic cell transplantation within 360 days prior to enrollment 4. CMV seropositive or had a donor who was CMV positive 5. One or both of the following: - CMV event* within the first 100 days post-transplant requiring anti-viral treatment - Receipt of CMV prophylaxis**(for at least 30 days) prior to registration. Continuation of letermovir prophylaxis after day 100 per institutional standard of care is permitted * CMV event defined as DNA detection or disease ** Anti-viral treatment or prophylaxis includes ganciclovir, valganciclovir, foscarnet, or letermovir 6. Meet at least one or more of criteria of the following: - HLA mismatch* - umbilical cord blood source** - GVHD*** - T-cell depletion**** - Human leukocyte antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B, or -DR, Haploidentical donor, Unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1 **Use of umbilical cord blood as stem cell source ***Acute or chronic GVHD requiring topical steroid for GI GVHD and/or systemic steroid treatment (>/= 1 mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 6 weeks prior to enrollment ****Subjects who have received partial or full T-cell depletion (with or without GVHD). T-cell depletion can be given as either ex-vivo or in-vivo for GVHD prophylaxis. T-cell depleting agents include, but are not limited to, anti-thymocyte globulin (ATG) and alemtuzumab Exclusion Criteria: Randomized Cohort: 1. Inability to fully comprehend the study website and study procedures 2. Any other condition, which in the opinion of the investigator would interfere with successful completion of this clinical trial 3. Morphological relapse (bone marrow or peripheral blood blast) prior to registration Observational Cohort: 1. Did not meet all inclusion criteria 2. Morphological relapse (bone marrow or peripheral blood blast) prior to registration |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas - MD Anderson Cancer Center - Infectious Diseases | Houston | Texas |
United States | University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine | Minneapolis | Minnesota |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Fred Hutchinson Cancer Research Center - Vaccine and Infectious Diseases | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of participants who have completed >90% of their recommended Cytomegalovirus (CMV) monitoring tests in the DBS and control arms | At one year after Hematopoietic cell transplantation (HCT) | ||
Secondary | Number of subjects in DBS and standard of care arms with end-organ Cytomegalovirus (CMV) disease, possible and proven/probable | By 1 year after Hematopoietic cell transplantation (HCT) | ||
Secondary | Number of subjects with finger-stick procedure-related Grade 3 AEs | By 1 year after Hematopoietic cell transplantation (HCT) | ||
Secondary | The total number of recommended Cytomegalovirus (CMV) monitoring tests that were completed per subject | By 1 year after Hematopoietic cell transplantation (HCT) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
Completed |
NCT00370006 -
Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
Completed |
NCT00386412 -
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
|
Phase 2 | |
Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
Completed |
NCT01354301 -
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
|
Phase 4 | |
Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00880789 -
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
|
Phase 1 | |
Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 | |
Completed |
NCT00194155 -
Cytomegalovirus (CMV) Infection in Pregnancy
|
N/A |